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Metabolic syndrome: sign of things to come
In a recent article in Vascular Health and Risk Management, Paoletti and colleagues
(2006) pointed out that individuals with metabolic syndrome (MS) have twice the
risk of dying and three times higher risk of having heart attacks or stroke compared
with individuals without this syndrome. Moreover, people with MS have a five-fold
greater risk of developing type-2 diabetes. Thus MS could become a leading cause
of morbidity/mortality in the world population (Paoletti et al 2006). In the current
issue of Vascular Health and Risk Management, Mathieu and colleagues (2006) have
proposed a link between MS and atherosclerosis suggesting that individual with the
syndrome have a substantially higher risk of coronary heart disease (CHD).
There is little doubt that changes in life style is a major contributor to MS. Recently,
it was reported that while the prevalence of MS was higher among Chinese women,
17.8% (95% confidence incidence [CI] 16.6–19.0] than Chinese men, 9.8% (CI 9.0–
10.6), the overall prevalence was higher in urban 18.6% (CI 17.6–19.6) compared
with rural areas, 12.7% (CI 10.7–13.1) (Gu et al 2005). Society has to recognize that
this syndrome is rapidly becoming a problem affecting the health of a large portion
of the population. Furthermore, as the population ages and people live longer, this
problem will become compounded if it is ignored.
It is essential that an appropriate definition should be employed to determine the
prevalence of this syndrome in a population. MS is characterized by abdominal
obesity, high blood pressure, dyslipidemia, and increased glucose concentration.
Currently there are three definitions of the syndrome, one proposed by US National
Cholesterol Education Program Adult Treatment Panel III (NCEP), another by World
Health Organization (WHO), and more recently one by International Diabetes
Federation (IDF) (Mathieu et al 2006; Paoletti et al 2006). Perhaps not surprisingly,
not all definitions present the appropriate gauge for classifying people of different
ethnic background with MS. For example, it has been suggested that the use of NCEP
criteria in Chinese and Asian populations could underestimate the prevalence of MS
(Tan et al 2004).
A recent study attempting to determine the prevalence of MS and cardiovascular
disease in an elderly Chinese population (age 60 to 95) residing in urban centers
such as Beijing revealed some interesting information in relation to the syndrome
and the cohort that was studied (He et al 2006). The prevalence of MS as defined by
IDE or NCEP was higher in females than males. Based on IDF criteria 34.8% and
54.1% for males (n=943) and females, (n=1391) respectively, were classified with
MS, whereas when employing the NCEP (glucose ≥5.6 mmol/l) criteria, 23.2% of
males and 46.1% of females were found with MS. He and colleagues (2006) also
reported that individuals with MS as defined by either NCEP or IDF criteria had a
significantly higher odds ratio (OR) for CHD (n=784), peripheral arterial disease
(PAD) (n=461) and stroke (n=378). The OR (CI) for cardiovascular disease in people
with MS as defined by IDF for CHD, PAD, stroke, and combined (CHD, PAD, and
stroke) (n=1219) were 1.69 (1.40–2.02), 1.42 (1.14–1.76), 1.58 (1.26–2.00) and 1.73
(1.46–2.07), respectively. The data was adjusted for gender, age, martial status,
education, exercise, alcohol consumption, cigarette smoking, and family history of
CHD or stroke. The OR (CI) for cardiovascular disease in people with MS as defined
by NCEP (glucose ≥5.6 mmol/l) for CHD, PAD, stroke and combined (CHD, PAD,Vascular Health and Risk Management 2006:2(3) 194
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and stroke) were 1.58 (1.31–1.90), 1.37 (1.10–1.70), 1.53
(1.21–1.94) and 1.57 (1.31–1.88), respectively. It is apparent
that the OR for cardiovascular disease associated with MS
as defined by IDF criteria reveals a stronger trend compared
with MS defined by NCEP, even when fasting glucose cutoff
was lowered to ≥5.6 mmol/l (He et al 2006). Determination
of the OR for cardiovascular disease in individuals with
MS as defined by IDF based on gender indicated 1.77 (1.34–
2.34) and 1.71 (1.37–2.13) for men and women, respectively.
Moreover, when analyses were carried out excluding the
diabetic patients (n=362; 15.5%), the OR for cardiovascular
disease associated with MS was somewhat reduced but
nonetheless, it was still significant. With this adjustment,
the OR in individuals with MS were 1.57 (1.28–1.91), 1.36
(1.07–1.73), 1.53 (1.18–1.99) and 1.55 (1.28–1.87), for
CHD, PAD, stroke, and combined (CHD, PAD, and stroke),
respectively. Based on the evidence presented by He and
colleagues (2006), it seems that MS is significantly linked
to a higher risk of cardiovascular disease in the population
that was studied.
It is expected that the prevalence of MS will rise over
the coming decades and appropriate steps are required to
address this issue. In general, there are three concerns that
need attention in relation to MS. First, it must be recognized
that MS is a major contributor to morbidity and mortality in
the population at large. Second, appropriate definition needs
to be sought and refined to accurately measure the correct
prevalence of MS within a population. Finally, suitable
public health education must be developed and implemented
to prevent the expected rise of MS and its sequelae from
becoming a worldwide epidemic.
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